SAGIMET BIOSCIENCES INC. - SERIES A COMMON STOCK

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat 

10 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

06 Jun 2024 02:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

16 May 2024 05:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

15 May 2024 05:00:00 By Nasdaq GlobeNewswire

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

07 May 2024 05:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

06 May 2024 05:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

22 Apr 2024 05:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

27 Mar 2024 13:01:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

25 Mar 2024 04:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

25 Mar 2024 03:15:00 By Nasdaq GlobeNewswire

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

29 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

25 Jan 2024 17:58:03 By Nasdaq GlobeNewswire

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

23 Jan 2024 14:45:51 By Nasdaq GlobeNewswire

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

22 Jan 2024 04:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

04 Dec 2023 05:00:01 By Nasdaq GlobeNewswire